PRS-300 series A

N/A

Report date: 2025/03/20 14:52:07

Base Information

Drug NamePRS-300 series A

Drug Alias Name300 series-A anticalin-antibody fusion proteins (Pieris Pharmaceuticals)dual CTLA-4 checkpoint inhibitor/anti-HER2 (Pieris Pharmaceuticals)300 series-A anticalins (Pieris)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2Cytotoxic T-Lymphocyte-Associated Antigen 4

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPieris Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesPieris Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A